SHORT COURSE OF PEMBROLIZUMAB FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION AND PEMBROLIZUMAB MAINTENANCE, IS EFFECTIVE IN HEAVILY PRE-TREATED REFRACTORY GRAY ZONE LYMPHOMA (SIE 2026) - Oct 6, 2026 - Abstract #SP087; "Mediastinal Gray-zone lymphoma (MGZL) is a B cell neo- plasm that lies on the biological spectrum between primary mediastinal (thymic) large B‑cell lymphoma (PMBCL) and no- dular sclerosis classical Hodgkin lymphoma (NS‑cHL), with overlapping clinical, histological, molecular and epigenetic features.Conventional CHOP-based chemotherapy regimens (R-CHOP or R-EPOCH) in first line and a salvage treatment including chemotherapy plus autologous stem cell transplan- tation (ASCT) in refractory/relapsed disease, often produce unsatisfactory results. The evidence of CD30 expression in MGZL, supported the use of Brentuximab Vedotin, an an- ti-CD30 antibody drug conjugate, in the treatment of the dis- ease with encouraging results...The patients are still in continuous complete metabolic response after 36 and 21 months, respective- ly.Our data, although limited to two individual cases, demon- strated that pembrolizumab is effective even in heavily pre- treated or..."
Clinical • IO biomarker • B Cell Lymphoma • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin's Lymphoma • Primary Mediastinal Large B-Cell Lymphoma • Transplantation • ALK • BCL2 • BCL6 • CD20 • CD79A • FCER2 • IRF4 • MME • PAX5 • PD-L1 • TNFRSF8
|
|
M. Di Palma1; G. Farina1; S. Iaccarino1; D. P. Abagnale1; F. Squame2; G. Marcacci3; F. Frigeri1
|